Lymphedema Awareness Month
Together, We Can End Breast Cancer-Related Lymphedema

Together, We Can End Breast Cancer-Related Lymphedema

SOZO® Digital Health Platform is the only FDA-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. A systemwide, cloud-based solution that is setting new standards in early detection and management of breast cancer-related lymphedema for patients across the care continuum.

Discover SOZO

Lymphedema is a Risk of Breast Cancer Treatment that Can Have a Devastating Impact to Breast Cancer Survivor Quality of Life


newly diagnosed breast cancer patients every year in the U.S.1

1 in 5

breast cancer patients will be impacted by lymphedema2


of breast cancer patients are at risk of arm lymphedema due to their treatment3

Do you feel lymphedema has impacted your quality of life?
91% of patients believe that care teams should offer cancer patients a Lymphedema Prevention Program
Source: 2022 ImpediMed Lymphedema Awareness Study
I have been fighting cancer for over 25 years now and developing secondary lymphedema has by far been the worst part.
Source: 2022 ImpediMed Lymphedema Awareness Study
Surviving with hand and arm lymphedema after breast cancer makes me second guess what I can and can't do on a daily basis.
Source: 2022 ImpediMed Lymphedema Awareness Study
I have been in cancer remission for over 10 years but I currently spend about 3 hours per day managing my lymphedema and wear compression 24/7.
Source: 2022 ImpediMed Lymphedema Awareness Study


NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship

The NCCN Guidelines® are consistent about the importance of early detection of lymphedema and use of an objective tool, such as bioimpedance spectroscopy.

Learn More

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 24, 2023. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.


BIS Technology Sets the Standard of Care for Lymphedema Detection

In PREVENT, the largest randomized controlled trial (RCT) for lymphedema prevention in breast cancer patients, 92% of patients with early detection using BIS and intervention did not progress to chronic lymphedema.

Discover the Power of BIS Technology


Improving Patient Outcomes with a Lymphedema Prospective Care Model

Using our SOZO Digital Health Platform with L-Dex, ImpediMed partners with you to implement a Lymphedema Prevention Program (LPP) to help detect lymphedema in breast cancer patients at the early stage, so that it can be treated and stopped from progressing to a lifelong condition.

Learn More About LPP



Northwell HealthMoffit Cancer CenterNSW GovernmentMacQuarie UniversityIcon GroupAstraZenecaSharp's LogoAtlantic Health SystemCleveland ClinicKU Medical CenterOhio State University


  1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program Cancer Stat Facts 2023. National Institutes of Health, 2023.
  2. Gillespie TC, et al. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018 Aug; doi: 10.21037/gs.2017.11.04.
  3. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. Atlanta: American Cancer Society; 2019.
  4. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022.